Stock comparison
Krystal Biotech
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
KRYS
Krystal Biotech
Market cap
$8.83B
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | KRYS | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 51C | 69B | MTD |
| Benjamin Graham | 74D | 65B | KRYS |
| Philip Fisher | 74C | 63C | KRYS |
| Peter Lynch | 58C | 66B | MTD |
| Joel Greenblatt | 59C | 68B | MTD |
| Charlie Munger | 64D | 74B | MTD |
| Terry Smith | 64D | 70B | MTD |
Side-by-side metrics
| Metric | KRYS | MTD |
|---|---|---|
| Market cap | $8.83B | $22.29B |
| P/E (TTM) | 39.9x | 25.3x |
| EV/EBIT | 52.9x | 21.6x |
| ROIC (TTM) | 13.85% | 36.09% |
| Gross margin | 92.79% | 57.79% |
| Net margin | 53.92% | 21.4% |
| Revenue CAGR 5y | - | 2.01% |
| EPS CAGR 5y | - | 6.12% |
| Debt / Equity | 0.0x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
KRYS leads on
- Net margin53.92%vs 21.4%+60%
- Gross margin92.79%vs 57.79%+38%
MTD leads on
- Debt / Equity-vs 0.0x+100%
- ROIC (TTM)36.09%vs 13.85%+62%
- Market cap$22.29Bvs $8.83B+60%
- EV/EBIT21.6xvs 52.9x+59%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.